## Juan Roldan-Saelzer

## Members of the WHO International Working Group for Drug Statistics Methodology

## **Biography**

Dr Juan Roldan-Saelzer graduated in 1990 as Chemist Pharmacist from University of Concepcion, Chile. He has PhD in Pharmaceutical Sciences and Diploma in Clinical Research at the University of Chile. He also received post-graduate education at the Universities of Valencia (Spain) and Groningen (Netherlands), in addition to the Pharmacovigilance training course by the WHO Collaborating Center, The Uppsala Monitoring Center in Sweden.

His professional activities have been focused on clinical care area, both in hospital and primary care, besides academic and on regulatory work, since 2010.

Dr Roldan-Saelzer is currently, and since 2011, the Head of Pharmacovigilance Sub-department, of the Department of National Medicines Agency, at the Institute of Public Health of Chile (National Regulatory Authority on drugs), and between August 2020 and July 2023 he was the deputy Head of the Department of National Medicines Agency. He has been a lecturer at different Universities in Santiago de Chile, teaching Clinical Pharmacy, Pharmacology, Pharmacovigilance and Pharmaceutical Care. He has also been part of postgraduate training programs at diverse Universities in Chile, and he is frequently invited to teach Pharmacovigilance in undergraduate classes, congresses, conferences and trainings, both in Chile and abroad.

Dr Roldan-Saelzer participated in the "Meeting of Experts in Clinical Pharmacology and Report of Adverse Drug Reactions as part of the undergraduate education in Pharmacovigilance: When two worlds meet", organized by WHO and the Pharmacovigilance Center of the Netherlands, Lareb, Hertogenbosch, Netherlands in November 2017. In 2020 he contributed to the WHO COVID-19 Vaccines safety surveillance manual. Currently he is a member of ISOP, Chilean Pharmacovigilance Society and a full member of the Chilean Academy of Pharmaceutical Sciences.

Since 2018 he is a member of the WHO International Working Group for Drugs Statistics Methodology and since 2019 he is on the WHO Expert Advisory Panel on Medicine Safety.